Q-omics provides the consensus-scored CCDC169-SOHLH2 profile across patient tissues and cancer cell-line models. CCDC169-SOHLH2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CCDC169-SOHLH2 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, CCDC169-SOHLH2 RNA expression shows 12,328 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LUAD, and UVM as cancer lineages where CCDC169-SOHLH2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC169-SOHLH2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC169-SOHLH2 survival associations across molecular data types. CCDC169-SOHLH2 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC169-SOHLH2 RNA expression–survival associations across cancer types. High CCDC169-SOHLH2 expression shows unfavorable associations in HNSC, LUAD and THCA, but favorable associations in UCS, KIRC and OV. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CCDC169-SOHLH2 RNA expression.
This table summarizes CCDC169-SOHLH2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC169-SOHLH2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC169-SOHLH2 shows lower tumor expression in BLCA, COAD, BRCA and THCA and higher tumor expression in LUAD and LUSC. The LUAD box plot shows higher CCDC169-SOHLH2 RNA expression in tumor versus normal tissue (log2 FC = +0.090, t-test p < 0.001).
This table shows molecular features associated with CCDC169-SOHLH2 in patient tissues and cancer cell lines. In patient samples, CCDC169-SOHLH2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC169-SOHLH2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC.
